Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
August 22, 2014

Recent Stories of Interest

From Drug Benefit News - Bids by Medicare Part D plans for the coming benefit year were particularly aggressive, as CMS disclosed late last month that the national average monthly bid amount dropped 7.5%. But this decline was up from a 5% reduction from 2013 to 2014 (see table, p. 7), and represents the second-largest drop in the average bid since 2007, the second year of the program, when rates fell 13%. Industry analysts suggest that large plan sponsors’ ability to control costs through preferred pharmacy networks is likely resulting in more competitive bids, and will continue to place pressure on smaller carriers. Read more

As the three publicly traded PBMs reported financial results for the second… Read more

The practice of 340B covered entities engaging in contract pharmacy arrangements has… Read more

Nearly two years after Novartis lost its patents on the popular hypertension… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

August 21, 2014
Were WAG Execs Ousted for Major Forecasting Error

Were two Walgreens execs ousted for major forecasting error?

August 19, 2014
Clone of FDA Approves Oral Drug for Gaucher Disease

FDA approves Genzyme’s Cerdelga (eliglustat) for certain adults with Gaucher disease type 1; drug is only first-line oral therapy for indication

August 18, 2014
FDA Approves Next-Generation Avonex for MS

FDA approves Biogen Idec’s Plegridy, a pegylated interferon to treat MS that’s dosed every two weeks; drug is next-generation version of Avonex, which has weekly dosing

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?